Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Costimulation-based immunotherapy for head and neck cancer.

Scott E Strome1, Lieping Chen

  • 1Department of Otolaryngology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. strome.scott@mayo.edu

Current Treatment Options in Oncology
|December 31, 2003
PubMed
Summary

Survival for squamous cell carcinoma of the head and neck (SCCHN) has not improved in 30 years. New therapies targeting SCCHN molecular pathways and immune responses are needed for better survival and quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.

Translational lung cancer research·2026
Same author

TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa.

Frontiers in immunology·2026
Same author

B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Why has immune "checkpoint" therapy failed in most clinical trials?

Journal for immunotherapy of cancer·2025
Same author

The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab.

Nature reviews. Clinical oncology·2025
Same author

PD-L1 and the dawn of modern cancer immunotherapy.

Nature medicine·2025

Area of Science:

  • Oncology
  • Immunology

Background:

  • Squamous cell carcinoma of the head and neck (SCCHN) significantly contributes to global cancer morbidity and mortality.
  • Current treatments (surgery, radiation, chemotherapy) are individualized but have not improved survival rates over the last three decades.
  • The long-term quality of life impact of modern SCCHN treatments remains largely unassessed.

Purpose of the Study:

  • To highlight the stagnation in survival rates for SCCHN over the past 30 years.
  • To emphasize the need for novel therapeutic strategies beyond current treatment modalities.
  • To underscore the importance of understanding SCCHN's molecular pathogenesis and immune response for future treatment development.

Main Methods:

  • Review of current treatment paradigms for SCCHN.

Related Experiment Videos

  • Analysis of survival data over the past 30 years.
  • Discussion of the limitations of existing therapies and the need for molecular and immunological insights.

    • Main Results:

    • Survival rates for SCCHN have remained largely unchanged despite advancements in surgical techniques and chemoradiotherapy.
    • The impact of novel organ-preservation strategies on patient quality of life is not well understood.
    • Significant gaps exist in understanding the molecular drivers and immune system's role in SCCHN.

    Conclusions:

    • Improved survival and quality of life for SCCHN patients necessitate the development of novel therapeutic alternatives.
    • Future treatments must be informed by a deeper understanding of SCCHN's molecular pathogenesis.
    • Targeting associated changes in the immune response presents a promising avenue for advancing SCCHN therapy.